Abstract Details

Title Updated US Prevalence Estimates Accounting for Racial and Ethnic Diversity for Trials and Therapies Targeting Mild Cognitive Impairment Due to Alzheimer’s Disease (AD) and Mild AD Dementia

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 011

Objective To update US prevalence estimates of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia, accounting for differences across Hispanic, non-Hispanic Black, and non-Hispanic White ethnoracial groups.

Background In light of new data on the underlying burden of Alzheimer’s disease and amyloid beta biomarker measures, updated prevalence estimates of the number of people living with MCI due to AD or mild AD dementia in the US are needed for clinical trial design, recruitment, and planning of healthcare needs.

Design/Methods A funnel to estimate the number of affected individuals was created using published information from the Centers for Disease Control and Prevention Wonder 2021 database, the Chicago Health and Aging Project, the Framingham Heart Study, and the Amyloid Biomarker Study. Results were compared with those of previously published sources.

Results The estimated number of people in the US aged >50 and >65 years with MCI due to AD is 6.9 million (5.7%) and 5.7 million (9.8%), respectively, and with mild AD dementia is 2.5 million (2.1%) and 2.5 million (4.2%), respectively. The total number of individuals aged ≥50 and ≥65 years with MCI due to AD or mild AD dementia is estimated as 9.4 million (7.7%) and 8.2 million (14.0%), respectively. These estimates are higher than those derived using references prior to 2021 or by collapsing race/ethnicity. Importantly, a large portion of the prevalent population remains undetected; thus, prevalence estimates may overestimate the number of patients currently diagnosed and readily available for clinical trial recruitment or treatment.

Conclusions Our updated estimates of US prevalence of MCI due to AD and mild AD dementia represent an increase from previous estimates, likely due to the higher prevalence in previously underrepresented populations. Future studies should include underrepresented populations and report results stratified by age and race/ethnicity.

Authors/Disclosures
Cai Gillis PRESENTER	Dr. Gillis has received personal compensation for serving as an employee of Biogen. Dr. Gillis has stock in Biogen.
	No disclosure on file
Mina Nejati (Biogen)	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��